1. Home
  2. MTX vs JANX Comparison

MTX vs JANX Comparison

Compare MTX & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Minerals Technologies Inc.

MTX

Minerals Technologies Inc.

HOLD

Current Price

$58.36

Market Cap

1.8B

Sector

Industrials

ML Signal

HOLD

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$34.23

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTX
JANX
Founded
1968
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.8B
IPO Year
1992
2021

Fundamental Metrics

Financial Performance
Metric
MTX
JANX
Price
$58.36
$34.23
Analyst Decision
Strong Buy
Buy
Analyst Count
3
11
Target Price
$79.67
$77.40
AVG Volume (30 Days)
182.7K
1.1M
Earning Date
10-23-2025
11-06-2025
Dividend Yield
0.75%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,071,200,000.00
$10,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.78
$89.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$49.54
$21.73
52 Week High
$84.05
$71.71

Technical Indicators

Market Signals
Indicator
MTX
JANX
Relative Strength Index (RSI) 51.11 70.08
Support Level $58.10 $28.25
Resistance Level $60.12 $35.34
Average True Range (ATR) 1.61 2.00
MACD 0.37 0.56
Stochastic Oscillator 59.74 88.56

Price Performance

Historical Comparison
MTX
JANX

About MTX Minerals Technologies Inc.

Minerals Technologies Inc mines, produces, and sells mineral-based products. The firm organizes itself into two segments: The Consumer & Specialties segment that derives maximum revenue, serves consumer end markets directly with mineral-to-market finished products and also provides specialty mineral-based solutions and technologies that are an essential component of its customers' finished products. The Engineered Solutions segment serves industrial end markets with engineered systems, mineral blends, and technologies that are designed to improve its customers' manufacturing processes and projects. The majority of revenue comes from the United States.

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: